Edwards Lifesciences Corporation (ew)

EW — Company Overview

Edwards Lifesciences Corporation (EW) trades on NYQ as part of the Healthcare peer group (Medical Devices).

EW — Business Description

EW represents a Medical Devices business in the Healthcare segment. Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue…

Official website: https://www.edwards.com.

EW — Investment Thesis

At a high level, EW offers exposure to Healthcare with metrics outlined below from public market data.

• Revenue is expanding at roughly 13.6% year-over-year (public data).
• Trailing P/E of 51.37× implies elevated growth expectations at the current price.
• Forward P/E (25.71×) is below trailing P/E — earnings may be expected to improve.
• Equity market capitalization is approximately $50.04B.

See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.

EW — Financial Health

Key financial health indicators for Edwards Lifesciences Corporation are derived exclusively from public data — no proprietary estimates.

Profit margin of 15.4% indicates solid bottom-line conversion. Positive free cash flow of $1.23B supports balance-sheet flexibility.

EW — Growth Outlook

Growth outlook for Edwards Lifesciences Corporation (EW) depends on demand trends in Medical Devices and the company's ability to convert revenue into sustainable earnings.

• Revenue growth of 13.6% indicates strong top-line momentum.
• Earnings declined -25.4% year-over-year — margin or volume pressure may be in play.
• Price is 9.8% below the 52-week high.
• Shares trade 20.1% above the 52-week low — limited rebound so far.

EW — Competitive Position

Edwards Lifesciences Corporation (EW) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.

• Competes within Healthcare, specifically in Medical Devices.
• Market capitalization of $50.04B places EW among large-cap peers.
• Gross margin near 77.8% may reflect pricing power or favorable mix.

EW — Summary

Edwards Lifesciences Corporation (EW) is a large-cap Healthcare company focused on Medical Devices, listed on NYQ. Last price $86.82 with market cap $50.04B. Trailing P/E 51.37×. Revenue grew 13.6% year-over-year per public data. Notable strengths include revenue growth of 13.6% year-over-year. Key watch items include earnings decline of -25.4% year-over-year. Premium Terminal tools for Edwards Lifesciences Corporation add ownership analytics, news, and richer estimate history beyond this public summary.